Thomas Ritter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1297539/publications.pdf

Version: 2024-02-01

56	3,541	27 h-index	56
papers	citations		g-index
59	59	59	5985 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Call for papers: Exploiting extracellular vesicles as therapeutic agents. Molecular Therapy, 2022, 30, 979.	8.2	1
2	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncolmmunology, 2021, 10, 1859263.	4.6	13
3	Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in mice. Stem Cell Research and Therapy, 2021, 12, 227.	5.5	7
4	Synthesized nanoparticles, biomimetic nanoparticles and extracellular vesicles for treatment of autoimmune disease: Comparison and prospect. Pharmacological Research, 2021, 172, 105833.	7.1	5
5	Artificial Cornea: Past, Current, and Future Directions. Frontiers in Medicine, 2021, 8, 770780.	2.6	29
6	TGF-Î ² 1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection InÂVivo. Molecular Therapy, 2020, 28, 2023-2043.	8.2	38
7	Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer. Cells, 2020, 9, 141.	4.1	24
8	Nanosensitive optical coherence tomography to assess wound healing within the cornea. Biomedical Optics Express, 2020, $11,3407$.	2.9	17
9	TNFâ€Î±/ Lâ€1βâ€"licensed mesenchymal stromal cells promote corneal allograft survival <i>via</i> myeloid cellâ€mediated induction of Foxp3 ⁺ regulatory T cells in the lung. FASEB Journal, 2019, 33, 9404-9421.	0.5	37
10	High-risk Corneal Transplantation: Recent Developments and Future Possibilities. Transplantation, 2019, 103, 2468-2478.	1.0	75
11	Antiâ€donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells. Immunology and Cell Biology, 2018, 96, 536-548.	2.3	5
12	Extracellular vesicles as modulators of wound healing. Advanced Drug Delivery Reviews, 2018, 129, 394-406.	13.7	116
13	Interspecies Incompatibilities Limit the Immunomodulatory Effect of Human Mesenchymal Stromal Cells in the Rat. Stem Cells, 2018, 36, 1210-1215.	3.2	21
14	Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation. Frontiers in Immunology, 2018, 9, 2666.	4.8	39
15	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. Cancer Immunology Research, 2018, 6, 1426-1441.	3.4	66
16	Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function. Frontiers in Immunology, 2017, 8, 987.	4.8	34
17	Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment. Frontiers in Immunology, 2017, 8, 1427.	4.8	10
18	Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?. Frontiers in Immunology, 2017, 8, 1626.	4.8	116

#	Article	IF	CITATIONS
19	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
20	vIL-10-overexpressing human MSCs modulate na \tilde{A} -ve and activated T lymphocytes following induction of collagenase-induced osteoarthritis. Stem Cell Research and Therapy, 2016, 7, 74.	5.5	25
21	Mesenchymal stem cell therapy to promote corneal allograft survival. Current Opinion in Organ Transplantation, 2016, 21, 559-567.	1.6	22
22	Development of a flow cytometry-based potency assay for measuring the in vitro immunomodulatory properties of mesenchymal stromal cells. Immunology Letters, 2016, 177, 38-46.	2.5	14
23	The Exosome ―A Naturally Secreted Nanoparticle and its Application to Wound Healing. Advanced Materials, 2016, 28, 5542-5552.	21.0	213
24	Corneal Immunosuppressive Mechanisms, Anterior Chamber-Associated Immune Deviation (ACAID) and Their Role in Allograft Rejection. Methods in Molecular Biology, 2016, 1371, 205-214.	0.9	15
25	Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. Peerl, 2016, 4, e2300.	2.0	55
26	Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. Molecular Therapy, 2015, 23, 812-823.	8.2	877
27	TNFÎ \pm and IL-1Î 2 influence the differentiation and migration of murine MSCs independently of the NF-Î 9 B pathway. Stem Cell Research and Therapy, 2014, 5, 104.	5.5	64
28	Chondrogenic Differentiation Increases Antidonor Immune Response to Allogeneic Mesenchymal Stem Cell Transplantation. Molecular Therapy, 2014, 22, 655-667.	8.2	76
29	Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?. Stem Cell Research and Therapy, 2014, 5, 99.	5.5	61
30	Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?. Stem Cells, 2013, 31, 2033-2041.	3.2	124
31	Gene Therapy Approaches to Prevent Corneal Graft Rejection: Where Do We Stand?. Ophthalmic Research, 2013, 50, 135-140.	1.9	9
32	Antiâ€donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunology and Cell Biology, 2013, 91, 40-51.	2.3	205
33	Donor Bone Marrow–derived Dendritic Cells Prolong Corneal Allograft Survival and Promote an Intragraft Immunoregulatory Milieu. Molecular Therapy, 2013, 21, 2102-2112.	8.2	13
34	Allogeneic Murine Mesenchymal Stem Cells: Migration to Inflamed Joints In Vivo and Amelioration of Collagen Induced Arthritis When Transduced to Express CTLA4Ig. Stem Cells and Development, 2013, 22, 3203-3213.	2.1	27
35	Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine, 2012, 16, 2094-2103.	3.6	215
36	Adenoviral Transduction of Mesenchymal Stem Cells: In Vitro Responses and In Vivo Immune Responses after Cell Transplantation. PLoS ONE, 2012, 7, e42662.	2.5	31

#	Article	IF	CITATIONS
37	Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1447-1456.	1.9	28
38	Enhanced lipoplexâ€mediated gene expression in mesenchymal stem cells using reiterated nuclear localization sequence peptides. Journal of Gene Medicine, 2010, 12, 207-218.	2.8	38
39	Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies. Human Gene Therapy, 2010, 21, 1641-1655.	2.7	272
40	Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease. Discovery Medicine, 2010, 9, 219-23.	0.5	17
41	Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation. Expert Review of Clinical Immunology, 2009, 5, 749-764.	3.0	12
42	Gene therapy in transplantation: Toward clinical trials. Current Opinion in Molecular Therapeutics, 2009, 11, 504-12.	2.8	2
43	Gene-Modified Mesenchymal Stem Cells Express Functionally Active Nerve Growth Factor on an Engineered Poly Lactic Glycolic Acid (PLGA) Substrate. Tissue Engineering - Part A, 2008, 14, 681-690.	3.1	48
44	Local Overexpression of Nerve Growth Factor in Rat Corneal Transplants Improves Allograft Survival., 2007, 48, 1043.		45
45	Effects of Spironolactone on Corneal Allograft Survival in the Rat. Ophthalmic Research, 2007, 39, 325-329.	1.9	7
46	Effects of interleukin-12p40 gene transfer on rat corneal allograft survival. Transplant Immunology, 2007, 18, 101-107.	1.2	26
47	Gene transfer of cyto-protective molecules in corneal endothelial cells and cultured corneas: Analysis of protective effects in vitro and in vivo. Biochemical and Biophysical Research Communications, 2007, 357, 302-307.	2.1	13
48	The influence of inducible costimulator fusion protein (ICOSIg) gene transfer on corneal allograft survival. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1515-1521.	1.9	14
49	Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. Journal of Gene Medicine, 2006, 8, 459-467.	2.8	47
50	Gene therapy in immune-mediated diseases of the eye. Progress in Retinal and Eye Research, 2003, 22, 277-293.	15.5	16
51	Improvements in Gene Therapy. BioDrugs, 2002, 16, 3-10.	4.6	79
52	Antigen-Dependent Transgene Expression in Kidney Transplantation: A Novel Approach Using Gene-Engineered T Lymphocytes. Journal of the American Society of Nephrology: JASN, 2002, 13, 511-518.	6.1	8
53	Corneal Allograft Rejection: Current Understanding. Ophthalmologica, 2001, 215, 254-262.	1.9	23
54	Immune tolerance and gene therapy in transplantation. Trends in Immunology, 2000, 21, 12-14.	7. 5	14

THOMAS RITTER

#	Article	IF	CITATIONS
55	STIMULATORY AND INHIBITORY ACTION OF CYTOKINES ON THE REGULATION OF hCMV-IE PROMOTER ACTIVITY IN HUMAN ENDOTHELIAL CELLS. Cytokine, 2000, 12, 1163-1170.	3.2	52
56	Adenovirus-Mediated Gene Transfer of Interleukin-4 to Corneal Endothelial Cells and Organ Cultured Corneas Leads to High IL-4 Expression. Experimental Eye Research, 1999, 69, 563-568.	2.6	36